Qairnel provides an AI-driven platform that screens large populations for early neurodegenerative signs and creates digital twins to predict disease progression, enabling precise patient stratification for clinical trials. The system shortens screening time, reduces required participant numbers, and delivers prognostic covariates in formats compatible with standard biostatistical workflows for pharma, biotech, and CROs.
Funding
Funding not disclosed
Founders
Product
Problem
Recruiting suitable participants for neurodegenerative disease trials is slow and inefficient, with long screening periods, high failure rates, and large sample sizes needed to achieve statistical power.
Solution
Qairnel offers an AI-driven platform that screens the general population for early signs of neurodegeneration and creates digital twins to predict disease progression. The system identifies fast‑progressing patients, generates prognostic covariates, and returns results in formats compatible with standard biostatistical workflows. By providing precise patient stratification, the platform reduces screening time from up to ten months to two months, lowers failure rates, and can cut required participant numbers by up to 50%, thereby increasing trial power and success probability. It also routes qualified individuals to trial sites, supporting faster post‑market studies and broader market access.
Target Audience
Primary customers are pharmaceutical and biotechnology companies running clinical trials for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders, as well as CROs that manage patient recruitment and screening.
Features
- AI models trained on 15+ years of neuroscience research that predict four‑year cognitive decline with validated accuracy
- Digital twin generation for each screened individual, delivering prognostic covariates usable in standard statistical analyses
- End‑to‑end trial‑ready workflow: secure data sharing, locked model execution, and rapid turnaround (<4 weeks after database lock)
- Large‑scale pre‑screening via the DocMemo platform, profiling tens of thousands of individuals across Europe and the US
- Automated patient referral to treatment centers and clinical trial sites
- Cloud‑based analytics with encrypted data handling and versioned model delivery